Deerfield Management Company, L.P.'s Form 4 filing
Bicara Therapeutics Inc. (BCAX) · filed Sep 17, 2024
- Accession no.
- 0001193805-24-001131
- Filed
- Sep 17, 2024, 6:16 PM ET
- Trade date
- Sep 17, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $1.26M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | 10% Owner, Other: Possible Members of 10% Group |
| Deerfield Mgmt L.P.CIK 0001010823 | 10% Owner, Other: Possible Members of 10% Group |
| Deerfield Partners, L.P.CIK 0001301041 | 10% Owner, Other: Possible Members of 10% Group |
| Flynn James ECIK 0001352546 | 10% Owner, Other: Possible Members of 10% Group |
| Deerfield Private Design Fund V, L.P.CIK 0001815437 | 10% Owner, Other: Possible Members of 10% Group |
| Deerfield Mgmt V, L.P.CIK 0001876688 | 10% Owner, Other: Possible Members of 10% Group |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2024 | Common Stock | CConversionAcquired | +862,587 | –F1 | – | 862,587 | Indirect | |
| Sep 17, 2024 | Common Stock | CConversionAcquired | +862,587 | –F1 | – | 862,587 | Indirect | |
| Sep 17, 2024 | Common Stock | PPurchaseAcquired | +35,000 | $18.00 | +$630,000 | 897,587 | Indirect | |
| Sep 17, 2024 | Common Stock | PPurchaseAcquired | +35,000 | $18.00 | +$630,000 | 897,587 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Preferred Stock automatically converted into approximately 0.1082 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-9.2435 reverse split of the Issuer's common stock effected by the Issuer in September 2024).
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.